Download PDF
Horm Metab Res 2021; 53(10): 692-698
DOI: 10.1055/a-1587-9211
Endocrine Research

Clinical Value and Role of miR-129-5p in Non-Alcoholic Fatty Liver Disease

Yuan Wang‡
1   Sub-Health Clinic of Physical Examination Center, Beijing Fengtai Hospital of Integrated Traditional Chinese and Western Medicine, Beijing, China
,
Yujia Feng‡
2   Department of Gastroenterology, People's Hospital of Rizhao, Rizhao, China
,
Han Zhang
3   Department of Liver Center, The Affiliated Hospital of Qingdao University, Qingdao, China
,
Qinghui Niu 
3   Department of Liver Center, The Affiliated Hospital of Qingdao University, Qingdao, China
,
Kun Liang
4   Department of Infectious Diseases, The Affiliated Hospital of Qingdao University, Qingdao, China
,
Cheng Bian
4   Department of Infectious Diseases, The Affiliated Hospital of Qingdao University, Qingdao, China
,
Hong Li‡
5   Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital,Tongji University School of Medicine, Shanghai, China
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

This study was to evaluate the expression of miR-129–5p in non-alcoholic fatty liver (NAFLD) patients and its clinical value and explore its regulatory effect on insulin resistance (IR). A total of 117 NAFLD patients and 110 healthy controls were included. The levels of miR-129-5p were detected by qRT-PCR. To assess the diagnostic value of miR-129-5p for NAFLD, the receiver operating characteristic curve (ROC) was established. C57Bl/6 mice were supplied with high-fat diet to establish NAFLD model. Intraperitoneal insulin tolerance test (IPITT) was carried out to evaluate the effect of miR-129-5p on IR in NAFLD animal model. miR-129-5p was highly expressed in the serum of NAFLD patients, and patients with HOMA-IR ≥2.5 had higher level of miR-129-5p than those with HOMA-IR <2.5. miR-129-5p had the ability to differentiate NAFLD patients from healthy individuals and might be associated with the development of IR. Serum miR-129-5p was positively correlated with the levels of HOMA-IR, BMI, total cholesterol (TC), and triglyceride (TG) in NAFLD patients. Downregulation of miR-129-5p regulates lipid metabolism and insulin sensitivity in NAFLD mice model. MiR-129-5p was upregulated in NAFLD patients and might be a potential diagnostic biomarker. The regulatory effect of miR-129-5p on NAFLD may function by regulating lipid accumulation and insulin sensitivity.

Key words

non-alcoholic fatty liver disease - insulin resistance - microRNA-129-5p - HOMA-IR


Publication History

Received: 29 March 2021

Accepted after revision: 11 August 2021

Article published online:
15 September 2021

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Takaki A, Kawai D, Yamamoto K. Molecular mechanisms and new treatment strategies for non-alcoholic steatohepatitis (NASH). Int J Mol Sci 2014; 15: 7352-7379
    CrossrefPubMedGoogle Scholar
  • 2 Younossi ZM, Koenig AB, Abdelatif D. et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64: 73-84
    CrossrefPubMedGoogle Scholar
  • 3 Stefanovic-Racic M, Perdomo G, Mantell BS. et al. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels. Am J Physiol Endocrinol Metab 2008; 294: E969-E977
    CrossrefPubMedGoogle Scholar
  • 4 Zhou M, Hu N, Liu M. et al. A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix. Biomed Res Int 2020; 5462063
    PubMed
  • 5 Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options. JHEP Rep 2019; 1: 312-328
    CrossrefPubMedGoogle Scholar
  • 6 Stefan N, Haring HU, Cusi K. Non-alcoholic fatty liver disease: Causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 2019; 7: 313-324
    CrossrefPubMedGoogle Scholar
  • 7 Sheka AC, Adeyi O, Thompson J. et al. Nonalcoholic Steatohepatitis: A Review. JAMA 2020; 323: 1175-1183
    CrossrefPubMedGoogle Scholar
  • 8 Friedman SL, Neuschwander-Tetri BA, Rinella M. et al. Mechanisms of NAFLD development and therapeutic strategies. Nat Med 2018; 24: 908-922
    CrossrefPubMedGoogle Scholar
  • 9 Younossi Z, Tacke F, Arrese M. et al. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Hepatology 2019; 69: 2672-2682
    CrossrefPubMedGoogle Scholar
  • 10 Mehta R, Otgonsuren M, Younoszai Z. et al. Circulating miRNA in patients with non-alcoholic fatty liver disease and coronary artery disease. BMJ Open Gastroenterol 2016; 3: e000096
    CrossrefPubMedGoogle Scholar
  • 11 Bartel DP. MicroRNAs: Target recognition and regulatory functions. Cell 2009; 136: 215-233
    CrossrefPubMedGoogle Scholar
  • 12 Piscopo P, Grasso M, Puopolo M. et al. Circulating miR-127-3p as a Potential Biomarker for Differential Diagnosis in Frontotemporal Dementia. J Alzheimers Dis 2018; 65: 455-464
    CrossrefPubMedGoogle Scholar
  • 13 Song Y, Li Z, He T. et al. M2 microglia-derived exosomes protect the mouse brain from ischemia-reperfusion injury via exosomal miR-124. Theranostics 2019; 9: 2910-2923
    CrossrefPubMedGoogle Scholar
  • 14 Fu X, Jin L, Han L. et al. miR-129-5p Inhibits Adipogenesis through Autophagy and May Be a Potential Biomarker for Obesity. Int J Endocrinol 2019; 5069578
    PubMed
  • 15 European Association for the Study of the L, European Association for the Study of D, European Association for the Study of O. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 2016; 59: 1121-1140
    CrossrefPubMedGoogle Scholar
  • 16 Shen C, Zhao CY, Wang W. et al. The relationship between hepatic resistin overexpression and inflammation in patients with nonalcoholic steatohepatitis. BMC Gastroenterol 2014; 14: 39
    CrossrefPubMedGoogle Scholar
  • 17 Hayashi Y, Ito Y, Naito H. et al. In utero exposure to di(2-ethylhexyl)phthalate suppresses blood glucose and leptin levels in the offspring of wild-type mice. Toxicology 2019; 415: 49-55
    CrossrefPubMedGoogle Scholar
  • 18 Wang XC, Zhan XR, Li XY. et al. MicroRNA-185 regulates expression of lipid metabolism genes and improves insulin sensitivity in mice with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 17914-17923
    CrossrefPubMedGoogle Scholar
  • 19 Dai LL, Li SD, Ma YC. et al. MicroRNA-30b regulates insulin sensitivity by targeting SERCA2b in non-alcoholic fatty liver disease. Liver Int 2019; 39: 1504-1513
    CrossrefPubMedGoogle Scholar
  • 20 Jampoka K, Muangpaisarn P, Khongnomnan K. et al. Serum miR-29a and miR-122 as Potential Biomarkers for Non-Alcoholic Fatty Liver Disease (NAFLD). Microrna 2018; 7: 215-222
    CrossrefPubMedGoogle Scholar
  • 21 Yu F, Wang X, Zhao H. et al. Decreased Serum miR-1296 may Serve as an Early Biomarker for the Diagnosis of Non-Alcoholic Fatty Liver Disease. Clin Lab 2019; 65: DOI: 10.7754/Clin.Lab.2019.190335
    PubMed
  • 22 Meroni M, Longo M, Erconi V. et al. mir-101-3p Downregulation Promotes Fibrogenesis by Facilitating Hepatic Stellate Cell Transdifferentiation During Insulin Resistance. Nutrients 2019; 11: 2597
    CrossrefPubMedGoogle Scholar
  • 23 Shan TD, Tian ZB, Jiang YP. Downregulation of lncRNA MALAT1 suppresses abnormal proliferation of small intestinal epithelial stem cells through miR1295p expression in diabetic mice. Int J Mol Med 2020; 45: 1250-1260
    PubMedGoogle Scholar
  • 24 Fu Q, Jiang H, Wang Z. et al. Injury factors alter miRNAs profiles of exosomes derived from islets and circulation. Aging (Albany NY) 2018; 10: 3986-3999
    CrossrefPubMedGoogle Scholar
  • 25 Yoon D, Lee SH, Park HS. et al. Hypoadiponectinemia and insulin resistance are associated with nonalcoholic fatty liver disease. J Korean Med Sci 2005; 20: 421-426
    CrossrefPubMedGoogle Scholar
  • 26 Drinda S, Grundler F, Neumann T. et al. Effects of Periodic Fasting on Fatty Liver Index-A Prospective Observational Study. Nutrients 2019; 11: 2601
    CrossrefPubMedGoogle Scholar
  • 27 Okubo H, Kushiyama A, Nakatsu Y. et al. Roles of Gut-Derived Secretory Factors in the Pathogenesis of Non-Alcoholic Fatty Liver Disease and Their Possible Clinical Applications. Int J Mol Sci 2018; 19: 3064
    CrossrefPubMedGoogle Scholar
  • 28 Eshraghian A, Iravani S, Azimzadeh P. The Association between Angiotensin II Type 1 Receptor Gene A1166C Polymorphism and Non-alcoholic Fatty Liver Disease and Its Severity. Middle East J Dig Dis 2018; 10: 96-104
    CrossrefPubMedGoogle Scholar
  • 29 Hegazy M, Saleh SA, Ezzat A. et al. Novel Application of the Traditional Lipid Ratios as Strong Risk Predictors of NASH. Diabetes Metab Syndr Obes 2020; 13: 297-305
    CrossrefPubMedGoogle Scholar